|
||
Obogen Pregnancy |
||
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Obogen is excreted into breast milk in small amounts. At 1 and 7 hours following a dose of Obogen, serum concentrations averaged 3.9 and 1.1 mcg/mL, respectively, while milk concentrations averaged 0.4 and 0.4 mcg/mL. The milk:plasma ratio averaged 0.11 and 0.44, respectively. Infants were fed one hour after administration of Obogen. Obogen was detected in the serum of 5 of 10 infants with an average serum concentration of 0.4 mcg/mL. The five other infants had undetectable levels (below 0.27 mcg/mL). Obogen is considered compatible with breast-feeding by the American Academy of Pediatrics.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|